BARING ASSET MANAGEMENT Ltd Has $1,323,000 Position in Pfizer, Inc. (PFE)
BARING ASSET MANAGEMENT Ltd continued to hold its stake in Pfizer, Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,389 shares of the biopharmaceutical company’s stock at the end of the second quarter. BARING ASSET MANAGEMENT Ltd’s holdings in Pfizer were worth $1,323,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Altfest L J & Co. Inc. raised its stake in Pfizer by 67.0% during the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after buying an additional 43,024 shares during the last quarter. HL Financial Services LLC raised its stake in Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after buying an additional 35,744 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Pfizer during the first quarter worth $13,342,000. Searle & CO. raised its stake in Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after buying an additional 38,500 shares during the last quarter. Finally, Hartford Financial Management Inc. raised its stake in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 835 shares during the last quarter. 69.34% of the stock is owned by institutional investors and hedge funds.
PFE has been the subject of a number of research reports. BMO Capital Markets restated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. UBS AG restated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $38.48.
ILLEGAL ACTIVITY WARNING: “BARING ASSET MANAGEMENT Ltd Has $1,323,000 Position in Pfizer, Inc. (PFE)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/11/21/baring-asset-management-ltd-has-1323000-position-in-pfizer-inc-pfe.html.
Pfizer, Inc. (NYSE:PFE) opened at $35.35 on Tuesday. The company has a market cap of $211,040.00, a P/E ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the previous year, the company earned $0.61 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer, Inc. will post 2.6 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.62%. Pfizer’s dividend payout ratio is presently 78.53%.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders sold a total of 366,557 shares of company stock valued at $12,532,406 in the last ninety days. 0.06% of the stock is owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.